🚀 Pharmidex at the Translational Science Summit on MND & Rare Dementias! 🧬
March 4, 2025
We’re excited to share that Janette Dalay Robertson, our Business Development Manager, will be attending the Translational Science Summit on MND and Rare Dementias this March 5th at Kings Place, London (9:00 AM - 5:30 PM).
This summit brings together leading researchers, clinicians, and industry professionals to accelerate therapeutic discoveries for neurodegenerative diseases like Motor Neuron Disease (MND) and rare dementias.
With a strong focus on collaboration and translational research, this event aligns perfectly with Pharmidex’s commitment to innovative drug discovery and development.
Looking to explore cutting-edge science and potential collaborations? Let’s connect! Reach out to Janette Dalay Robertson to schedule a meeting.
#Pharmidex #MND #RareDementias #TranslationalScience #DrugDiscovery #Neurodegeneration #LifeSciences
We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. 👩🔬 👨🔬 Welcome to the team, Gabrielle and Mohammed!
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: ✅ Bitter-tasting APIs ✅ Unpalatable excipients ✅ The success of taste-masking strategies ✅ Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
